Harrow IncNASDAQ:HROW
- LAST PRICE18.1700
- TODAY'S CHANGE (%)0.2100 (1.1693%)
- Bid / Lots16.3100/ 1
- Ask / Lots18.6500/ 1
- Open / Previous Close17.9100 / 17.9600
- Day Range
- 52 Week Range
- Volume220,423
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | HROW |
|---|---|---|
| 09:32 ET | 2866 | 17.91 |
| 09:38 ET | 540 | 17.8979 |
| 09:39 ET | 100 | 17.835 |
| 09:41 ET | 1000 | 17.91 |
| 09:43 ET | 2910 | 18.09 |
| 09:45 ET | 1100 | 18.1 |
| 09:48 ET | 200 | 18.13 |
| 09:50 ET | 357 | 18.07 |
| 09:52 ET | 100 | 18.1 |
| 09:54 ET | 100 | 18.11 |
| 09:57 ET | 2361 | 18.07 |
| 09:59 ET | 200 | 18.055 |
| 10:01 ET | 400 | 18.13 |
| 10:08 ET | 200 | 18.215 |
| 10:10 ET | 1640 | 18.225 |
| 10:14 ET | 978 | 18.14 |
| 10:15 ET | 2647 | 18.14 |
| 10:17 ET | 6559 | 18.13 |
| 10:21 ET | 397 | 18.083 |
| 10:24 ET | 200 | 18.05 |
| 10:28 ET | 123 | 18.1237 |
| 10:32 ET | 100 | 18.11 |
| 10:37 ET | 200 | 18.07 |
| 10:42 ET | 3611 | 18.235 |
| 10:48 ET | 200 | 18.225 |
| 10:51 ET | 3225 | 18.2028 |
| 10:55 ET | 107 | 18.175 |
| 11:00 ET | 100 | 18.14 |
| 11:02 ET | 2376 | 18.11 |
| 11:04 ET | 500 | 18.14 |
| 11:06 ET | 300 | 18.16 |
| 11:09 ET | 670 | 18.19 |
| 11:15 ET | 1593 | 18.23 |
| 11:20 ET | 4097 | 18.23 |
| 11:24 ET | 1097 | 18.27 |
| 11:26 ET | 1289 | 18.26 |
| 11:27 ET | 100 | 18.26 |
| 11:29 ET | 5163 | 18.2 |
| 11:31 ET | 200 | 18.21 |
| 11:33 ET | 100 | 18.19 |
| 11:36 ET | 100 | 18.19 |
| 11:40 ET | 600 | 18.17 |
| 11:42 ET | 200 | 18.16 |
| 11:58 ET | 471 | 18.2199 |
| 12:05 ET | 400 | 18.16 |
| 12:12 ET | 200 | 18.15 |
| 12:21 ET | 3113 | 18.155 |
| 12:23 ET | 100 | 18.15 |
| 12:25 ET | 800 | 18.18 |
| 12:30 ET | 500 | 18.16 |
| 12:34 ET | 100 | 18.19 |
| 12:36 ET | 400 | 18.19 |
| 12:38 ET | 600 | 18.225 |
| 12:39 ET | 300 | 18.1945 |
| 12:41 ET | 550 | 18.2156 |
| 12:43 ET | 500 | 18.21 |
| 12:45 ET | 100 | 18.21 |
| 12:48 ET | 3388 | 18.17 |
| 12:50 ET | 3895 | 18.135 |
| 12:52 ET | 221 | 18.12 |
| 12:54 ET | 732 | 18.12 |
| 12:56 ET | 596 | 18.1244 |
| 12:57 ET | 500 | 18.128 |
| 01:01 ET | 600 | 18.13 |
| 01:06 ET | 805 | 18.25 |
| 01:08 ET | 100 | 18.19 |
| 01:10 ET | 300 | 18.2 |
| 01:14 ET | 100 | 18.19 |
| 01:17 ET | 100 | 18.21 |
| 01:19 ET | 100 | 18.21 |
| 01:24 ET | 100 | 18.21 |
| 01:26 ET | 300 | 18.17 |
| 01:28 ET | 200 | 18.16 |
| 01:37 ET | 100 | 18.11 |
| 01:42 ET | 100 | 18.09 |
| 01:48 ET | 500 | 18.1 |
| 02:00 ET | 200 | 18.03 |
| 02:02 ET | 1308 | 17.98 |
| 02:08 ET | 954 | 17.94 |
| 02:09 ET | 800 | 17.96 |
| 02:13 ET | 400 | 17.93 |
| 02:15 ET | 1000 | 17.9447 |
| 02:18 ET | 100 | 17.93 |
| 02:22 ET | 600 | 17.99 |
| 02:24 ET | 400 | 17.96 |
| 02:27 ET | 100 | 17.96 |
| 02:33 ET | 200 | 17.98 |
| 02:36 ET | 1461 | 17.92 |
| 02:38 ET | 200 | 17.9004 |
| 02:42 ET | 200 | 17.89 |
| 02:47 ET | 100 | 17.88 |
| 02:51 ET | 458 | 17.8979 |
| 02:54 ET | 100 | 17.88 |
| 02:56 ET | 958 | 17.945 |
| 02:58 ET | 100 | 17.97 |
| 03:00 ET | 907 | 17.995 |
| 03:02 ET | 100 | 18.005 |
| 03:03 ET | 5893 | 18.19 |
| 03:05 ET | 4134 | 18.15 |
| 03:07 ET | 305 | 18.1 |
| 03:09 ET | 950 | 18.11 |
| 03:12 ET | 100 | 18.12 |
| 03:14 ET | 4398 | 18.08 |
| 03:16 ET | 800 | 18.115 |
| 03:18 ET | 100 | 18.125 |
| 03:21 ET | 200 | 18.12 |
| 03:23 ET | 200 | 18.15 |
| 03:25 ET | 1200 | 18.135 |
| 03:27 ET | 1000 | 18.1201 |
| 03:30 ET | 1111 | 18.13 |
| 03:32 ET | 100 | 18.14 |
| 03:34 ET | 200 | 18.15 |
| 03:36 ET | 822 | 18.09 |
| 03:38 ET | 2027 | 18.11 |
| 03:39 ET | 100 | 18.15 |
| 03:41 ET | 1565 | 18.155 |
| 03:43 ET | 2392 | 18.105 |
| 03:45 ET | 100 | 18.11 |
| 03:48 ET | 827 | 18.09 |
| 03:50 ET | 2400 | 18.1399 |
| 03:52 ET | 500 | 18.15 |
| 03:54 ET | 2568 | 18.14 |
| 03:56 ET | 2317 | 18.17 |
| 03:57 ET | 4291 | 18.162 |
| 03:59 ET | 3108 | 18.17 |
Jun 6, 2024
Jun 5, 2024
Harrow Announces 52-Week Data from VEVYE(R) ESSENCE-2 Open-Label Extension Study, from 7:00AM ET on Wednesday Jun 05, 2024 by Dow Jones
7:00AM ET on Wednesday Jun 05, 2024 by Dow Jones
Jun 3, 2024
DJ Harrow Is Maintained at Buy by Lake Street, from 11:11AM ET on Monday Jun 03, 2024 by Dow Jones
11:11AM ET on Monday Jun 03, 2024 by Dow Jones
May 15, 2024
DJ Harrow Is Maintained at Buy by Craig-Hallum, from 2:02PM ET on Wednesday May 15, 2024 by Dow Jones
2:02PM ET on Wednesday May 15, 2024 by Dow JonesDJ Harrow Price Target Raised to $29.00/Share From $26.00 by B. Riley Securities, from 10:22AM ET on Wednesday May 15, 2024 by Dow Jones
10:22AM ET on Wednesday May 15, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Harrow Inc | 616.0M | -20.0x | --- |
SIGA Technologies Inc | 527.0M | 7.0x | -28.78% |
Esperion Therapeutics Inc | 426.3M | -2.8x | --- |
Bavarian Nordic A/S | 2.1B | 13.9x | --- |
Xeris Biopharma Holdings Inc | 344.0M | -5.0x | --- |
Daiichi Sankyo Co Ltd | 67.8B | 54.9x | --- |
Company Information
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Contact Information
- Headquarters
- 102 WOODMONT BLVD, SUITE 610NASHVILLE, TN, United States 37215
- Phone
- 615-733-4731
- Fax
- 858-345-1745
Executives
- Chairman of the Board, Chief Executive Officer
- Mark Baum
- Chief Financial Officer, Corporate Secretary
- Andrew Boll
- President and Chief Executive Officer of ImprimisRx, Chief Commercial Officer
- John Saharek
- Lead Independent Director
- Perry Sternberg
- Independent Director
- Adrienne Graves
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $634.0M |
|---|---|
Revenue (TTM) | $138.7M |
Shares Outstanding | 35.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.76 |
EPS | $-0.91 |
Book Value | $2.01 |
P/E Ratio | -20.0x |
Price/Sales (TTM) | 4.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -5.56% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
